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graft required for transplantation to remain cost saving compared to dialysis; the 
number of future transplants or improvement in graft survival required to avoid the 
transplant waiting list increasing. The study utilises UK costs and future costs and 
benefits were discounted at 3.5% Results: Over a 10-year projected time horizon 
the total per-patient cost saving associated with remaining on dialysis compared 
to transplant was £276,330; however, a cost saving was conditional upon achieving 
at least 3-years of functioning graft. In order to maintain the transplant waiting list 
at approximately 7,000, the number of annual transplants conducted would need to 
increase from 2,645 in 2010 to 3,640 by 2022 (a 37.6 % increase). At current activity 
levels the transplant waiting list is projected to increase by approximately 1,983; 
improvement in graft survival could potentially reduce this by 941. ConClusions: 
For kidney transplantation to be cost saving recipients must maintain at least 3 
years of functioning graft. As early graft failure also impacts on future transplant 
waiting time, management strategies that maximize graft survival will reduce costs 
and improve service delivery targets.
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CoMPaRison of alteRnative Methods of ResouRCe-use data 
ColleCtion foR the eConoMiC evaluation of health CaRe 
inteRventions: a Case study in fRail oldeR PeoPle
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University of Nottingham, Nottingham, UK
objeCtives: Economic evaluations require patient-level resource-use to estimate 
patient costs. The National Programme for IT (2002) prompted UK health and 
social care to record patient-level resource-use using Electronic Administration 
Records (EAR’s). Retrieving EAR’s is labour intensive, but may provide better infor-
mation than self-report methods, such as the Client Service Receipt Inventory 
(CSRI), particularly in cognitively impaired people. Study objectives are to examine 
agreement, and associated cost estimates, between resource-use obtained from 
EAR's or CSRI in frail older (≥70) participants. Methods: Health and social care 
data for 247 patients (193 cognitively impaired) were sought retrospectively six 
months post-index hospital admission. Resource-use data were collected using 
a self/proxy-reported modified CSRI, and EAR systems for primary (PC), second-
ary (SC), and social (SoC) care. Lin’s coefficient (ρc) assessed agreement between 
methods, where <0.4 = poor agreement. Results: Agreement between EAR and 
CSRI ‘per contact’ resource-use was: good, primary care (ρc = 0.60); fair, outpa-
tient care (ρc = 0.53). Agreement was incomparable for social care due to different 
resource-use recording formats; CSRI’s inpatient care question was removed due 
to the preferred detailed information available in EAR’s. EAR data provided detailed 
patient care information, such as diagnosis and procedure type, allowing improved 
allocation of unit costs. Difference in mean cost per patient between methods 
varied by service (CSRI/EAR (£): PC = 61/433; SC = 7281/7833; SoC = 252/886); CSRI 
inpatient costs were simulated assuming perfect agreement with EAR, but using 
level of information outlined within the CSRI. ConClusions: EAR’s provided 
more complete patient costs. Using EAR’s reduces burden upon participants, which 
is important for frail and cognitively impaired people. Although the CSRI can be 
modified and simple to administer, poor recall and inadequate detail about patient 
care contacts prevented accurate patient-level cost estimation. Gaining access to 
EAR’s is labour intensive, but recommended in cognitively impaired participants.
PRM22
CaRbon Cost-effeCtiveness of CoCooning iMMunization against 
PeRtussis in england and Wales: an eCologiCal PeRsPeCtive
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objeCtives: The cost-effectiveness of pertussis vaccination has been demonstrated 
for various vaccination strategies. However, beyond financial cost expressed in mon-
etary terms vaccines also incur environmental cost expressed in CO2equivalent 
(CO2e) emission. By preventing disease, this cost might be offset by avoided events 
such as doctors’ visits, hospital bed stays, medication, amongst other items. In 
this exercise we examine the CO2e savings of a pertussis (dTpa) booster dose for 
cocooning in England and Wales. We propose a complementary measure to the 
classical Incremental Cost-Effectiveness Ratio that includes environmental cost 
instead of monetary cost. Methods: The cradle to gate carbon footprint (from 
raw material extraction, to manufacturing, to disposal) for a typical dTpa vaccine 
dose was assessed to estimate the total amount of CO2e emitted (“carbon cost”). 
A previously published static epidemiological model was used to account for the 
reduction in incidence of pertussis. Two scenarios were compared: the current per-
tussis vaccination schedule and the same schedule with additionally a cocooning 
strategy. Results: For each dose of a dTpa vaccine manufactured, results show 
approximately 1kg of CO2e was emitted. The model shows cocooning immuniza-
tion against pertussis is projected to reduce the reported incidence of pertussis in 
young infants. Results also show that due to the reduction in emitted CO2e after 
the introduction of a cocooning strategy, vaccination is an acceptable alternative 
to the current strategy to control pertussis infection. ConClusions: The method 
presented demonstrates how traditional economic models can be utilized to model 
environment features. Assessment of the cradle to gate carbon footprint of a vaccine 
provides a preliminary view of both the impact on the environmental in general 
and on the environment profile of health care in the UK.
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objeCtives: In 2012, NICE initiated a multiple treatment assessment reviewing all 
licensed biologics for the treatment of rheumatoid arthritis (RA) previously treated 
experienced and high-quality source for post-approval studies. Elaborated manage-
ment processes in multi-country panels guarantee a constant quality of the panel 
over geographies.
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ClassifiCation of Cognitive dysfunCtion and Cognitive noRMal 
using sCoRes fRoM fouR Cognitive assessMents in Patients With 
dePRessive disoRdeR
Maruff P.1, Walker V.2, Samp J.3, Essoi B.2, Kurlander J.L.2, Akhras K.S.3
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objeCtives: Cognitive functioning is a multidimensional attribute comprising 
various domains including attention, memory, executive function, and psycho-
motor speed. The number of impacted domains and magnitude of deficits that 
equate to a classification of cognitive dysfunction (CD) are unclear. This analysis 
examined criteria used for CD classification in an observational study of depressed 
patients. Methods: A large US health plan was used to identify depressed patients 
with a newly prescribed antidepressant. Consenting, eligible patients were inter-
viewed by telephone and completed a structured assessment of cognitive function 
measuring 4 domains: verbal episodic memory (Hopkins Verbal Learning Test-
Revised), attention (Digit Span Forward), working memory (Digit Span Backward), 
and executive function (D-KEFS-Letter Fluency Test). Patients were classified into 2 
groups based on test scores relative to normative data. “CD” was defined as patients 
with ≥ 2 scores that were ≥ 1.5 standard deviations (SD) below the normative mean 
(criterion 1) or patients with ≥ 3 scores that were ≥ 1.0 SD below the normative 
mean (criterion 2). Patients not meeting either of these were classified as “cognitive 
normal (CN).” T-tests compared differences between the groups across cognitive 
domains. Results: Of 564 eligible patients who completed the study, 45% met 
criteria for CD. Among these, 63% met both criteria for classification of CD, 19% met 
only criterion 1, and 18% met only criterion 2. The percentage of patients with scores 
≥ 1.0 SD below the mean and ≥ 1.5 SD below the mean were significantly higher in the 
CD group compared to the CN for all 4 tests. Mean scores on all domains were signifi-
cantly lower (P < 0.001) in the CD group compared to the CN group. ConClusions: 
Among patients with depression, those with cognitive dysfunction had significantly 
worse functioning across all domains. This suggests that the criteria appropriately 
identified a subset of patients with impaired cognitive functioning.
ReseaRCh on Methods – Cost Methods
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objeCtives: Adequate reflection of disease progression and costs over time is 
essential in cost-effectiveness analyses (CEAs) based on health state transition mod-
els. However costing studies normally investigate the burden of metastatic breast 
cancer (MBC) without explicitly examining impact of specific disease states on 
health care costs over time. The objective of this study was to assess time-dependent 
costs of different health states of human epidermal receptor 2 (HER-2) positive 
MBC and the factors contributing to these costs. Methods: In The Netherlands, 
HER-2 positive MBC patients were identified in three different hospitals. Resource 
use was collected during 24 months, which was linked to unit costs and related 
to time with respect to date of MBC diagnosis, disease progression and death for 
each individual patient. Subsequently, monthly costs for different health states 
were calculated. Finally, a nonlinear mixed effect modelling approach was used 
to provide a quantitative description of the time course of cumulative progression 
costs. Results: Costs during stable disease were constant over time with a mean 
of € 3,236. In contrast, monthly costs for progressive disease demonstrated a change 
over time with the largest costs in the first two months after diagnosis (p< 0.005). The 
developed mixed effect model adequately described cumulative cost time course 
and associated variability. During the last months of life, costs varied over time, with 
the last month of life as the most expensive one with a mean of € 4,522 per patient 
per month. ConClusions: To reflect costs of HER-2 positive MBC accurately in 
Markov models, costs stable disease can be defined time-independent, however, 
costs of progressive disease should be defined time dependent, and costs related to 
the final months of life should be modeled as such. The mixed effect model we have 
developed could now be considered for adequate description of the time-dependent 
cost of progressive disease.
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united KingdoM
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objeCtives: The UK has an ageing and growing population and the prevalence 
of renal replacement therapy (RRT) has grown by 5.0% annually since 2000. RRT 
accounts for over 2% of the current NHS expenditure. Transplantation increases 
survival, improves quality of life and maintenance costs are less than dialysis. 
Despite increasing rates of transplantation, an estimated 7,000 patients remain 
on the waiting list. The objective of this study was to quantify the relationship 
between graft survival time, total estimated cost and the number of projected 
patients on the transplant waiting list. Methods: We utilized a population based 
simulation model with published disease progression, incidence and prevalence 
parameters specific to the UK. We evaluated the number of years of functioning 
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deCReMents in deCision Models
Cure S.1, Despiégel N.2, Guerra I.1
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objeCtives: In cost-utility analyses (CUAs) it is common to estimate the utility 
of patients while on treatment or when experiencing comorbidities by adjusting 
their baseline utility with the treatment/comorbidity-related utility decrement. 
This study assessed the impact of adjusting patients’ baseline utility with additive 
versus multiplicative utility decrements on the lifetime quality-adjusted life years 
(QALYs) in CUAs for two chronic illnesses. Methods: Two Markov models were 
developed. In the first model, utility during treatment was obtained by adjust-
ing the baseline utility with the treatment-related utility decrement; treatment 
was given for one year. In the second model, utilities with comorbidities were 
obtained from external sources and were combined with the health state utilities 
by considering the lowest value. In both models, the response of the multiplicative, 
additive and the combined approach was investigated by comparing the number 
of QALYs gained over a lifetime. Results: In the first model, as treatment was 
only given during the first year, the impact on the number of QALYs gained over 
a lifetime was minimal. Thus, a similar incremental cost-effectiveness ratio per 
QALY (ICER/QALY) was obtained with all the approaches. In contrast, for the second 
model, the number of QALYs gained over a lifetime between the approaches was 
significantly different. This is because comorbidities were experienced during a 
longer period of time. Consequently, the difference in ICER/QALY was also substan-
tial. ConClusions: When developing CUA, either a multiplicative or combined, 
rather than additive, approach should be used to calculate the utility of patients 
during treatment or with comorbidities, using utility decrements, if consider-
able uncertainty is present in the baseline utility. However, if QALYs gained with 
treatment or with comorbidities represent only a small fraction of the overall 
QALYs gained, the difference between the approaches is not expected to have a 
significant impact on the results.
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Moran P., Teljeur C., Murphy L., O’Neill M., Harrington P., Ryan M.
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objeCtives: The European Union’s (EU) 2011 Directive on cross-border health care 
establishes the right of EU citizens to receive treatment abroad and be reimbursed 
in their home country. While the focus has been on patient mobility and access, it 
may also facilitate international outsourcing of services between countries. This 
research examines the methodological challenges in evaluating the costs and 
consequences of cross-border service provision. Methods: Using the example 
of deep brain stimulation (DBS) treatment in Ireland, we conducted an economic 
analysis of the provision of cross-border services from the perspective of the public 
health system. This included an analysis of clinical and cost-effectiveness, ethical 
and societal implications and the challenges of integrating care between sepa-
rate health systems. Results: Accurate modelling of the provision of a new or 
expanded service serves as the basis for evaluating costs, impact on patients and 
potential gaps in continuity of care. Cost minimisation analysis may be appropriate 
under some circumstances, with due regard to the importance of patient selec-
tion and follow up. Cross-border services may have significant implications for 
equity of access, with potential negative consequences for those most in need of 
treatment. Results of the economic analysis indicate that a national DBS service 
in Ireland would cost an additional € 20,900 per patient over 10 years. The potential 
for anomalies within health systems with a mixture of private and public funders 
is highlighted, with the difference being reduced to € 4,100 per patient in a single 
payer scenario. ConClusions: Health care funding structures can impact signifi-
cantly on the cost-effectiveness of cross-border services, even when differences in 
the actual cost of care are minimal. Given the externalities involved, analysis from 
the payer perspective may be too narrow for the economic evaluation of routine 
cross-border provision of elective services.
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eMPiRiCal evidenCe foR the validity and Reliability of ResouRCe-use 
MeasuRes based on Patient ReCall: a systeMatiC RevieW
Thorn J., Noble S., Moore T., Hollingworth W.
University of Bristol, Bristol, UK
objeCtives: Accurate measurement of resource use is required for economic 
evaluations alongside clinical trials. Patient-completed questionnaires are com-
monly employed as a means of collecting data; however, concerns over data qual-
ity persist, and there is little certainty about best practice. This review collates the 
evidence concerning the validity and reliability of resource-use measures based 
on patient recall with the aim of aiding health economists in developing better 
measures. Methods: A search strategy incorporating terms covering health care 
resources, utilisation, patient-reported measures and validation/reliability con-
cepts was applied to the MEDLINE, EMBASE and PsycINFO bibliographic databases. 
Studies were included if they reported original research to inform costing studies, 
and were about patient or proxy self-reports of direct health care-related resource 
use in which a comparator (to assess validity or reliability) was specified. Studies 
were excluded if they were not in English or if they assessed general population 
surveys. Reference and citation lists of included studies were hand searched to 
identify additional studies. Data on study and population characteristics, type of 
instrument, recall period and sample size were extracted. Results and conclusions 
concerning the validity and reliability of reports of types of resource use consumed 
(e.g.medication, inpatient stays) were also extracted. Results: A total of 13,367 
abstracts were identified as potentially relevant through the database searches. 
Following abstract and full-text screening, 60 articles were deemed relevant, with a 
further 9 identified through hand searching. The majority focused on adults (60/69), 
with conventional DMARDs only. The sequence of treatments used after the fail-
ure of first biologic treatment was to be included as part of the cost-effectiveness 
modelling. We therefore built a model to match the treatment pathway for first-line 
biologics and beyond. Methods: We researched the treatment pathway and exist-
ing cost-effectiveness models in order to create an appropriate model. We rebuilt 
the model used by the technology assessment group in TA195, which considered 
second-line biologics and beyond. We adapted this model to reflect the current 
treatment pathway and consider first line biologics. Results: We created a patient 
simulation model, which generated a cohort of virtual patients and tracked their 
costs and QALYs over the pathway. Patients began treatment with a biologic, and 
could discontinue at month 6 due to an adverse event (AE), in which case they 
switched to a different biologic, with first-line efficacy. Patients who did not have 
an AE discontinued at month 6 if their DAS 28 improvement was insufficient. After 
discontinuation at month 6, or later, patients next received rituximab, unless con-
traindicated. If rituximab was contraindicated, or the patient had an AE by month 
6, they moved onto another biologic treatment, after which they received a DMARD 
treatment sequence (including palliative care). Patients who had insufficient DAS28 
response on rituximab at month 6 switched to tocilizumab (unless received previ-
ously), after which they received the DMARD sequence. Patients who had sufficient 
DAS28 improvement with rituximab remained on rituximab long-term, until they 
received the DMARD treatment sequence. Patients could exit the model at any point 
if they died. ConClusions: We used robust methodology and clinical rationale to 
assess the cost-effectiveness of licenced treatments reflected across NICE’s recom-
mended treatment pathway for RA.
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objeCtives: In 2013, NCPE assessed the cost-effectiveness of subcutaneous (SC) 
abatacept as a first line biologic for the treatment of rheumatoid arthritis (RA), 
compared to existing biologics. It was necessary to consider the treatment path-
way beyond first line biologics. We therefore built a model to match the treatment 
pathway for first line biologics and beyond. Methods: We used our individual 
patient sampling model for England and Wales as a starting point to create a model 
which considers biologic cycling, to match the treatment pathway in Ireland. We 
differentiated between the efficacy of a biologic at first line, and at second line 
or later. Results: We created a model which could be used to calculate the cost-
effectiveness of biologics for the treatment of RA in Ireland. Patients first received 
treatment with SC abatacept, intravenous abatacept, adalimumab, etanercept, 
infliximab, certolizumab pegol or golimumab. If they experienced an adverse event 
(AE) on that treatment within 6 months, they switched to another biologic at first 
line efficacy. If not, their response to treatment was tested using the DAS28: if this 
improved by 1.2 or more, their time on treatment was sampled from a Weibull 
distribution, otherwise they discontinued at month 6. The patient then moved onto 
a randomly sampled second line biologic, which was either one of the first line bio-
logics or rituximab. The time on second line biologic was sampled from a Weibull 
distribution, and then the patient moved onto a third line biologics (second line 
biologics and tocilizumab). The patient cycled through the biologics until they died, 
or had received all 8 treatments. After 8 biologics, remaining patients received 
leflunomide, cyclosporin, azathioprine and palliative care. ConClusions: We 
used robust methodology and clinical rationale to model the treatment pathway of 
biologics for RA in Ireland and facilitated cost-effectiveness comparison between 
first line biologics.
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a systeMatiC RevieW of eConoMiC evidenCe in hePatitis C: Methods 
used in ReCent eConoMiC evaluations
Woods M.S.1, Kiri S.2, Ling C.1, McCrink L.1, Zimovetz E.1, Hass B.3
1RTI Health Solutions, Manchester, UK, 2Boehringer Ingelheim Ltd., Bracknell, UK, 3Boehringer 
Ingelheim GmbH, Ingelheim, Germany
objeCtives: To perform a systematic literature review of economic evidence 
for genotype 1 hepatitis C virus (HCV) treatments and to summarise and assess 
the methods used in recent economic evaluations. Methods: Multiple data-
bases were searched to identify economic evaluations in patients with genotype 
1 HCV. Detailed review methods are presented elsewhere. Results: 53 economic 
analyses and 17 Health Technology Assessment (HTA) documents were identified. 
Most economic analyses were performed using lifetime horizon Markov models, all 
for interferon-containing regimens. Most were performed in the United Kingdom 
(UK) (n = 13), United States (n = 13), or Germany (n = 7). Two recent National 
Institute for Health and Care Excellence (NICE) submissions were included: tel-
aprevir triple therapy (with peginterferon plus ribavirin) and boceprevir triple 
therapy, for previously treated and untreated patients. The models used were 
different; however their structures and some inputs were based on previous 
NICE appraisals for peginterferon plus ribavirin. There were a number of limita-
tions found in the included economic evaluations, which may have affected the 
cost-effectiveness outcomes: 1) The models did not adequately capture all health 
benefits and costs in their quality-adjusted life-year calculations; 2) The models 
did not account for the possibility of benefits caused by reduced transmission of 
HCV; 3) The models did not incorporate patient factors that may influence disease 
progression; 4) Modelling of subgroups may have been insufficient, particularly 
as the understanding of patient and viral factors that predict treatment response 
grows; and 5) Some made generalisations for the compensated cirrhosis popula-
tion that were not comparable with the UK population. ConClusions: Recent 
economic models have generally adhered to previous iterations of HCV models and 
have not evolved with our knowledge of the disease. In light of upcoming treat-
ment alternatives, model refinement may be necessary to capture the increasingly 
complex treatment decisions that will be required.
